Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Outlook Therapeutics (OTLK) over the last 8 years, with Q4 2025 value amounting to $881150.0.

  • Outlook Therapeutics' Share-based Compensation fell 7600.63% to $881150.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $6.1 million, marking a year-over-year increase of 669.04%. This contributed to the annual value of $8.9 million for FY2025, which is 6523.09% up from last year.
  • According to the latest figures from Q4 2025, Outlook Therapeutics' Share-based Compensation is $881150.0, which was down 7600.63% from $1.8 million recorded in Q3 2025.
  • Over the past 5 years, Outlook Therapeutics' Share-based Compensation peaked at $3.7 million during Q4 2024, and registered a low of $881150.0 during Q4 2025.